What's New
-
August 4, 2023
"SCAD and Kyoto University have started a joint research project to realize cell therapy and regenerative medicine using Schwann cells."
SCAD and Kyoto University have entered into a joint research agreement as of August 1, 2023 with Associate Professor Ryosuke Ikeguchi of Kyoto University Hospital and Professor Tomoki Aoyama of Kyoto University Graduate School of Medicine for the development of a new cellular medicine using Schwann cells produced by SCAD. We are aiming at new cell therapy and regenerative medicine for nerve damage such as peripheral nerve injury, by using the Schwann cells which have been used for drug discovery assays in SCAD.
Schwann cells, the major glial cells of the nervous system, are considered to be deeply involved in the regeneration and repair of neurons and axons. However, to date, it has been difficult to produce them stably from human pluripotent stem cells or other sources, and so far, little progress has been realized in their practical application as cellular medicines. We have improved and optimized the differentiation induction method for Schwann cells and have succeeded in efficient and stable production of Schwann cells from human pluripotent stem cell lines.
In the joint research with Kyoto University, we will start pre-clinical experiments using animal disease models to examine the possibility of clinical application of Schwann cells produced by SCAD by testing their effectiveness in neural repair and other aspects. When promising results are obtained in the animal experiments, we will plan to start clinical research for the world's first cell therapy and regenerative medicine by using Schwann cells. -
January 6, 2022
-
December 21, 2021
-
December 1, 2021
RIKEN BDR (Center for Biosystems Dynamics Research) has signed a joint research agreement with SCAD.
The Masumoto Laboratory ( Research Leader: Hidetoshi Masumoto, M.D., Ph.D., Senior Researcher) at the RIKEN BDR ( Kobe, Hyogo, Japan) is developing technology to evaluate cardiac function by applying cardiomyocyte tissue generated from iPS cells and microdevice technology. SCAD has provided some of the evaluation devices to Masumoto Laboratory. SCAD will collaborate with them to commercialize technology to evaluate the toxicity/safety and responses of the myocardial function to drugs. In addition, by using patient-derived disease-specific iPS cells, we will develop rare disease models, and as a next step, we will also study the discovery of therapeutic drugs that can improve the conditions recapitulated in these models.
-
November 11, 2021
Mr. Tetsuya Matsuura, Executive Vice President and other executives of SME SUPPORT JAPAN (the Organization for Small & Medium Enterprises and Regional Innovation, Japan) visited SCAD to inspect our activities to support drug discovery research based on iPS cells related technologies.
In addition to Mr. Matsuura, Mr. Yasuaki Nakajima, Director General of Kansai Head Office, and Mr. Kazuhisa Matsuo, Director General of Startup and Venture Business Support Division, visited SCAD and inspected the status of our development of disease model cells based on iPS cells derived from patient blood and the discovery of therapeutic drugs by using these cells.
SCAD has been developing these technologies with the support of the Ministry of Economy, Trade and Industry (METI) and a grant from KYOTO Industrial Support Organization 21 (Kyoto Prefecture). Although it is still under development, they understood that SCAD is proceeding to recapitulate disease conditions at the cellular level and to evaluate its drug response. -
October 7, 2021
We will exhibit at "BioJapan 2021" held at Pacifico Yokohama from October 13th to 15th. The latest information of our technology is exhibited, including neurological disorder models with patient-derived iPS cell lines, evaluation systems for muscle contractile force, and live-cell imaging chamber for microscopic observation.
-
October 1, 2021
Our project was adopted as a "2021 Kyoto Economic Gardening Support Enhancement Project" of KYOTO Industrial Support Organization 21.
-
May 12, 2021
The Japan External Trade Organization (JETRO) has released a video interview with our CEO.
JETRO has released a promotional video to introduce the innovation ecosystem in the life science field at the center of western Japan, Kansai region to the world. Together with Bayer in Kobe and AstraZeneca in Osaka, SCAD (Stem Cell & Device Laboratory, Inc.) in Kyoto was introduced in the promotional video.
Kensuke Kato, PhD, CEO of SCAD, is interviewed and explains an overview of the company's activities, development of iPS cell-based disease model cells for rare diseases, and drug discovery using these cells. -
October 14, 2020
We will exhibit at "BioJapan 2020" held at Pacifico Yokohama from October 14th to 16th.
-
September 25, 2020
The paper is about a study by Japanese researchers including Associate Professor Ikuo Suzuki of Tohoku Institute of Technology, our technical advisor, and ETH Zurich. It stated that by culturing iPS-derived neurons in three dimensions on oriented fibers using our cell device, the functionality is enhanced compared to two-dimensional culture, and that it is extremely effective in functional analysis of nerve cell populations.
-
September 24, 2020
Prof. Norio Nakatsuji, Chief Advisor, received "Future Creation Invention Award".
-
September 1, 2020
Our project was adopted as a "2020 Corporate Forest / Industry-Academia Forest Promotion Project" of KYOTO Industrial Support Organization 21.
- May 8, 2020
- February 19, 2020
- February 19, 2020
-
January 3, 2020
Our efforts for rare diseases were covered and broadcasted as news in "NHK / Kansai NEWS WEB (broadcast on January 3, 2020)".
- December 23, 2019
- December 16, 2019
-
December 16, 2019
We have entered into a joint research agreement with Kyoto Prefectural University of Medicine regarding the development of a disease model aimed at developing a treatment for Charcot-Marie-Tooth disease, which is one of the intractable hereditary neurological diseases.
-
November 11, 2019
Our projecty was adopted as a "2019 Next Generation Regional Industry Promotion Project" of KYOTO Industrial Support Organization 21.
-
September 26, 2019
We will exhibit at "BioJapan 2019" held at Pacifico Yokohama from October 9th to 11th.
-
June 3, 2019
At the 46th Annual Meeting of the Japanese Society of Toxicology, we will give a poster presentation on neuronal devices in collaboration with Associate Professor Ikuo Suzuki of Tohoku Institute of Technology, our joint research partner.
-
May 27, 2019
Our efforts for cell production of Charcot-Marie-Tooth disease model were introduced in the oral presentation "Latest topics in Charcot-Marie-Tooth disease" made by Professor Masanori Nakagawa, Vice President of Kyoto Prefectural University of Medicine, at the 60th Annual Meeting of the Japan Neurological Society.
-
May 25, 2019
We were selected as a "Companies Driving Regional Growth" by the Ministry of Economy, Trade and Industry.
Recommended by Kyoto City and Kyoto Prefecture, we were selected as a "Companies Driving Regional Growth" as a regional core company that will drive the regional economy. -
February 19, 2019
At the 10th Annual Meeting of the Japan Society for Safety and Pharmacology, we will give a poster presentation on neuronal devices in collaboration with Associate Professor Ikuo Suzuki of Tohoku Institute of Technology, our joint research partner.
-
February 19, 2019
We will exhibit at the 5th Regenerative Medicine Industrialization Exhibition (Osaka).
- December 21 ,2018
-
November 20 ,2018
Prof. Norio Nakatsuji, Chief Advisor, will give an opening lecture at an international conference.Our Chief Advisor, Norio Nakatsuji, Professor Emeritus of Kyoto University, will give an opening lecture at Cell Therapy Asia 2018 to be held in Kobe on December 6-7, 2018. Prof. Nakatsuji co-chairs the Organizing Committee of the Conference.
-
September 24 ,2018
Prof. Norio Nakatsuji, Chief Advisor, will give a keynote speech at an international conference.Our Chief Advisor, Norio Nakatsuji, Professor Emeritus of Kyoto University, will give a keynote speech at SelectBio Stem Cells in Drug Discovery & Toxicity Screening 2018 (San Diego, California) in October 2018.
- September 20 ,2018
- August 14 ,2018
- July 23 ,2018
-
March 21,2018
Notice of joint research with RIKEN
-
December 22 ,2017
Our Chief Advisor, Prof. Norio Nakatsuji, has been selected as a recipient of the 2018 Stem Cell and Regenerative Medicine Action Award from the Regenerative Medicine Foundation. Prof. Nakatsuji will be awarded the International Leadership Award for his outstanding and numerous contributions not only as a university person but also as an entrepreneur and philanthropist in fields of stem cells and regenerative medicine. The award ceremony will be held at the 13th World Stem Cell Summit (WSCS) evening reception held in Miami, Florida, USA in January 2018.
-
October 27 ,2017
Our research paper was published in Stem Cell Reports.
A paper on myocardial tissue using nanofibers for drug evaluation and transplantation by Prof. Norio Nakatsuji, Chief Advisor, Professor Emeritus of Kyoto University was published in Stem Cell Reports.
- October 17 ,2017
-
October 13,2017
Our project was adopted as a "2017 Industry-Academia Collaboration Promotion Project" of KYOTO Industrial Support Organization 21.
- September 29 ,2017
-
May 17 ,2017
World Advanced Therapies & Regenerative Medicine Congress 2017 (2017/5/17-19 London)
Prof. Norio Nakatsuji, Chief Advisor, will give a keynote speech. -
March 27 ,2017
We were certified as A rank by the Kyoto City Venture Business Connoisseurs Committee.
-
February 10 ,2017
The 8th Japan Safety Pharmacology Association (JSPS) Academic year (2017/2/10-11 The University of Tokyo)
We will give a poster presentation.
"SCAD-MT cardiomyocyte: human pluripotent stem cell-derived cardiomyocyte micro-tissues that show maturation and functional stability promoted by using aligned nanofibers"
-
December 6 ,2016
World Stem Cell Summit 2016 (2016/12/6-9 West Palm Beach, Florida)
Prof. Norio Nakatsuji, Chief Advisor, will give the opening remarks.
Prof. Nakatsuji will host the 5th Japan Summit.
Margaret Anne Craig, CCO, will introduce our technology at the 5th Japan Summit.
"3D micro tissue models of cardiac stem cells utilizing nanofiber technology exhibit more maturity and stability for acute and chronic drug discovery functional and structural assays"
-
October 5 ,2016
Cell & Gene Meeting on the Mesa 2016 (2016/10/5-7 San Diefo, California)
Prof. Norio Nakatsuji, Chief Advisor, will introduce our technology.
"SCAD-MT cardiomyocyte: Human pluripotent stem cell-derived cardiomyocyte micro-tissues that show promoted maturation and functional stability promoted by using aligned nanofibers"
-
September 18 ,2016
Safety Pharmacology Society 2016 (2016/9/18-21 Vancouver)
We will give a poster presentation.
"SCAD-MT cardiomyocyte: human pluripotent stem cell-derived cardiomyocyte micro-tissues that show promoted maturation and functional stability promoted by using aligned nanofibers"
-
June 15 ,2016
We implemented a series A third-party allotment.
-
April 12 ,2016
Investment Seminar on Life Sciences (Promoters : SCOTTISH Development International / KANAGAWA Pref.)
Prof. Norio Nakatsuji, Chief Advisor, will give a lecture. -
April 5 ,2016
Stem Cell in Drug Discovery 2016
Prof. Norio Nakatsuji, Chief Advisor, will give a keynote speech. -
March 22 ,2016
CiRA/ISSCR International Symposia 2016
Dr. Liu Li, Technical Advisor, will give a poster presentation. -
March 17 ,2016
The 15th Congress of the Japanese Society for Regenerative Medicine
Dr. Liu Li, Technical Advisor, will give an oral presentation.